A phase II study of capecitabine plus cisplatin in metastatic triple-negative breast cancer patients pretreated with anthracyclines and taxanes

A phase II study of capecitabine plus cisplatin in metastatic triple-negative breast cancer patients pretreated with anthracyclines and taxanes

ID：39776989

大?。?.15 MB

頁(yè)數(shù)：20頁(yè)

時(shí)間：2019-07-11

A phase II study of capecitabine plus cisplatin in metastatic triple-negative breast cancer patients pretreated with anthracyclines and taxanes_第1頁(yè)
A phase II study of capecitabine plus cisplatin in metastatic triple-negative breast cancer patients pretreated with anthracyclines and taxanes_第2頁(yè)
A phase II study of capecitabine plus cisplatin in metastatic triple-negative breast cancer patients pretreated with anthracyclines and taxanes_第3頁(yè)
A phase II study of capecitabine plus cisplatin in metastatic triple-negative breast cancer patients pretreated with anthracyclines and taxanes_第4頁(yè)
A phase II study of capecitabine plus cisplatin in metastatic triple-negative breast cancer patients pretreated with anthracyclines and taxanes_第5頁(yè)
資源描述：

《A phase II study of capecitabine plus cisplatin in metastatic triple-negative breast cancer patients pretreated with anthracyclines and taxanes》由會(huì)員上傳分享，免費(fèi)在線閱讀，更多相關(guān)內(nèi)容在學(xué)術(shù)論文-天天文庫(kù)。

1、CancerBiology&TherapyISSN:1538-4047(Print)1555-8576(Online)Journalhomepage:http://www.tandfonline.com/loi/kcbt20AphaseIIstudyofcapecitabinepluscisplatininmetastatictriple-negativebreastcancerpatientspretreatedwithanthracyclinesandtaxanesQiaoLi,QingLi,PinZhang,PengYuan,JiayuWang,FeiMa,YangLuo

2、,YingFan,RuigangCai&BingheXuTocitethisarticle:QiaoLi,QingLi,PinZhang,PengYuan,JiayuWang,FeiMa,YangLuo,YingFan,RuigangCai&BingheXu(2015):AphaseIIstudyofcapecitabinepluscisplatininmetastatictriple-negativebreastcancerpatientspretreatedwithanthracyclinesandtaxanes,CancerBiology&Therapy,DOI:10.1

3、080/15384047.2015.1095400Tolinktothisarticle:http://dx.doi.org/10.1080/15384047.2015.1095400Acceptedonline:15Oct2015.SubmityourarticletothisjournalViewrelatedarticlesViewCrossmarkdataFullTerms&Conditionsofaccessandusecanbefoundathttp://www.tandfonline.com/action/journalInformation?journalCod

4、e=kcbt20AphaseIIstudyofcapecitabinepluscisplatininmetastatictriple-negativebreastcancerpatientspretreatedwithanthracyclinesandtaxanes11111111QiaoLi,QingLi,PinZhang,PengYuan,JiayuWang,FeiMa,YangLuo,YingFan&Ruigang11,*Cai,BingheXu1DepartmentofMedicalOncology;CancerHospital,ChineseAcademyofMedi

5、calSciences(CAMS)andPekingUnionMedicalCollege;Beijing,ChinaCorrespondenceto:B.H.Xu;Email:xubinghe@medmail.com.cnAbstractBackground:Cisplatinisaneffectiveagentfortriple-negativebreastcancer(TNBC)andsynergisticactivitybetweencisplatinandcapecitabinehasbeendemonstratedbyinvitroandinvivostudies.

6、Thisstudywasdesignedasaprospectiveclinicaltrialtoevaluatetheefficacyandsafetyofcapecitabinepluscisplatin(XP)regimeninmetastaticTNBCpatientspretreatedwithanthracyclinesandtaxanes.PatientsandMethods:Thirty-threepatientswithmetastaticTNBCwhohadanthracyclinesand2taxanesaspriortherapyweretreatedw

7、ithcapecitabine2000mg/morallyonday1through142pluscisplatin75mg/mintravenouslyonday1ofa21-daycycle,followedbycapecitabinemaintenancemedicationsafteramaximumof6cycles.Theprimaryendpointwasobjectiveresponserate(ORR)andthesecondaryendpointsincludedprog

當(dāng)前文檔最多預(yù)覽五頁(yè)，下載文檔查看全文

此文檔下載收益歸作者所有

當(dāng)前文檔最多預(yù)覽五頁(yè)，下載文檔查看全文
溫馨提示：
1. 部分包含數(shù)學(xué)公式或PPT動(dòng)畫的文件，查看預(yù)覽時(shí)可能會(huì)顯示錯(cuò)亂或異常，文件下載后無(wú)此問(wèn)題，請(qǐng)放心下載。
2. 本文檔由用戶上傳，版權(quán)歸屬用戶，天天文庫(kù)負(fù)責(zé)整理代發(fā)布。如果您對(duì)本文檔版權(quán)有爭(zhēng)議請(qǐng)及時(shí)聯(lián)系客服。
3. 下載前請(qǐng)仔細(xì)閱讀文檔內(nèi)容，確認(rèn)文檔內(nèi)容符合您的需求后進(jìn)行下載，若出現(xiàn)內(nèi)容與標(biāo)題不符可向本站投訴處理。
4. 下載文檔時(shí)可能由于網(wǎng)絡(luò)波動(dòng)等原因無(wú)法下載或下載錯(cuò)誤，付費(fèi)完成后未能成功下載的用戶請(qǐng)聯(lián)系客服處理。